Biosyent Common Stock Shares Outstanding vs Net Receivables Analysis

RX Stock

CAD 11.52 0.18 1.54%

Biosyent financial indicator trend analysis is way more than just evaluating Biosyent prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Biosyent is a good investment. Please check the relationship between Biosyent Common Stock Shares Outstanding and its Net Receivables accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Biosyent. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Common Stock Shares Outstanding vs Net Receivables

Common Stock Shares Outstanding vs Net Receivables Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Biosyent Common Stock Shares Outstanding account and Net Receivables. At this time, the significance of the direction appears to have almost no relationship.

The correlation between Biosyent's Common Stock Shares Outstanding and Net Receivables is 0.15. Overlapping area represents the amount of variation of Common Stock Shares Outstanding that can explain the historical movement of Net Receivables in the same time period over historical financial statements of Biosyent, assuming nothing else is changed. The correlation between historical values of Biosyent's Common Stock Shares Outstanding and Net Receivables is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Common Stock Shares Outstanding of Biosyent are associated (or correlated) with its Net Receivables. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Receivables has no effect on the direction of Common Stock Shares Outstanding i.e., Biosyent's Common Stock Shares Outstanding and Net Receivables go up and down completely randomly.

Correlation Coefficient

0.15

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Common Stock Shares Outstanding

The total number of shares of a company's common stock that are currently owned by all its shareholders.

Net Receivables

Most indicators from Biosyent's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Biosyent current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Biosyent. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

At this time, Biosyent's Sales General And Administrative To Revenue is fairly stable compared to the past year. Enterprise Value Over EBITDA is likely to climb to 11.61 in 2024, whereas Selling General Administrative is likely to drop slightly above 6 M in 2024.

	2021	2022	2023	2024 (projected)
Total Revenue	28.6M	27.9M	31.6M	33.2M
Depreciation And Amortization	457.1K	451.0K	455.3K	478.1K

Total Revenue Depreciation And Amortization

Biosyent fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Shares Outstanding	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Current Deferred Revenue	Net Receivables	Short Term Investments	Common Stock	Other Liab
Total Assets		-0.04	-0.24	0.96	1.0	0.78	-0.5	1.0	0.96	0.57	0.93	0.15	0.99	0.15	0.83	0.59	-0.14	0.96	1.0	0.25	0.65	0.4	0.96	0.86	-0.64	0.61
Short Long Term Debt Total	-0.04		0.41	-0.1	-0.03	-0.08	-0.41	-0.09	-0.09	0.37	-0.19	0.13	0.02	0.94	-0.26	0.07	-0.5	-0.1	-0.02	-0.95	0.14	0.33	-0.07	-0.27	0.45	0.12
Other Current Liab	-0.24	0.41		-0.11	-0.26	-0.22	0.08	-0.28	-0.15	-0.11	-0.32	-0.16	-0.23	0.36	-0.14	-0.21	0.0	-0.15	-0.23	-0.42	-0.26	0.17	-0.32	-0.22	0.2	-0.21
Total Current Liabilities	0.96	-0.1	-0.11		0.94	0.78	-0.39	0.95	0.99	0.46	0.9	0.02	0.93	0.09	0.89	0.48	-0.12	0.99	0.96	0.32	0.51	0.48	0.91	0.87	-0.75	0.47
Total Stockholder Equity	1.0	-0.03	-0.26	0.94		0.76	-0.52	1.0	0.95	0.58	0.93	0.15	0.99	0.16	0.82	0.59	-0.14	0.94	1.0	0.23	0.68	0.37	0.96	0.85	-0.62	0.65
Property Plant And Equipment Net	0.78	-0.08	-0.22	0.78	0.76		-0.43	0.77	0.74	0.53	0.78	0.45	0.78	-0.03	0.6	0.8	-0.01	0.87	0.78	0.23	0.29	0.54	0.68	0.62	-0.6	0.1
Net Debt	-0.5	-0.41	0.08	-0.39	-0.52	-0.43		-0.49	-0.32	-0.99	-0.31	-0.2	-0.61	-0.38	0.02	-0.56	0.42	-0.41	-0.52	0.37	-0.66	-0.61	-0.35	0.0	-0.16	-0.48
Retained Earnings	1.0	-0.09	-0.28	0.95	1.0	0.77	-0.49		0.96	0.56	0.93	0.13	0.99	0.11	0.83	0.59	-0.11	0.95	1.0	0.29	0.66	0.36	0.96	0.87	-0.65	0.63
Accounts Payable	0.96	-0.09	-0.15	0.99	0.95	0.74	-0.32	0.96		0.4	0.91	0.02	0.93	0.12	0.92	0.44	-0.07	0.97	0.96	0.32	0.52	0.37	0.95	0.92	-0.76	0.52
Cash	0.57	0.37	-0.11	0.46	0.58	0.53	-0.99	0.56	0.4		0.39	0.24	0.68	0.34	0.06	0.63	-0.39	0.5	0.59	-0.31	0.65	0.65	0.42	0.08	0.07	0.46
Non Current Assets Total	0.93	-0.19	-0.32	0.9	0.93	0.78	-0.31	0.93	0.91	0.39		0.24	0.88	0.02	0.88	0.55	-0.02	0.92	0.91	0.37	0.54	0.32	0.88	0.87	-0.67	0.52
Non Currrent Assets Other	0.15	0.13	-0.16	0.02	0.15	0.45	-0.2	0.13	0.02	0.24	0.24		0.16	0.07	-0.04	0.72	-0.09	0.13	0.13	-0.18	0.18	-0.12	0.04	0.01	0.25	0.06
Cash And Short Term Investments	0.99	0.02	-0.23	0.93	0.99	0.78	-0.61	0.99	0.93	0.68	0.88	0.16		0.18	0.74	0.64	-0.18	0.94	0.99	0.17	0.7	0.45	0.93	0.79	-0.57	0.64
Common Stock Shares Outstanding	0.15	0.94	0.36	0.09	0.16	-0.03	-0.38	0.11	0.12	0.34	0.02	0.07	0.18		0.0	0.04	-0.58	0.06	0.16	-0.87	0.23	0.27	0.15	-0.04	0.29	0.27
Inventory	0.83	-0.26	-0.14	0.89	0.82	0.6	0.02	0.83	0.92	0.06	0.88	-0.04	0.74	0.0		0.26	0.03	0.86	0.82	0.47	0.32	0.14	0.87	0.95	-0.84	0.38
Other Current Assets	0.59	0.07	-0.21	0.48	0.59	0.8	-0.56	0.59	0.44	0.63	0.55	0.72	0.64	0.04	0.26		-0.14	0.59	0.59	0.02	0.35	0.29	0.45	0.35	-0.2	0.22
Other Stockholder Equity	-0.14	-0.5	0.0	-0.12	-0.14	-0.01	0.42	-0.11	-0.07	-0.39	-0.02	-0.09	-0.18	-0.58	0.03	-0.14		-0.09	-0.15	0.46	-0.3	-0.17	-0.1	0.1	-0.26	-0.22
Total Liab	0.96	-0.1	-0.15	0.99	0.94	0.87	-0.41	0.95	0.97	0.5	0.92	0.13	0.94	0.06	0.86	0.59	-0.09		0.96	0.31	0.48	0.51	0.89	0.85	-0.74	0.41
Total Current Assets	1.0	-0.02	-0.23	0.96	1.0	0.78	-0.52	1.0	0.96	0.59	0.91	0.13	0.99	0.16	0.82	0.59	-0.15	0.96		0.23	0.66	0.41	0.96	0.85	-0.63	0.62
Short Term Debt	0.25	-0.95	-0.42	0.32	0.23	0.23	0.37	0.29	0.32	-0.31	0.37	-0.18	0.17	-0.87	0.47	0.02	0.46	0.31	0.23		-0.05	-0.23	0.3	0.49	-0.66	-0.02
Intangible Assets	0.65	0.14	-0.26	0.51	0.68	0.29	-0.66	0.66	0.52	0.65	0.54	0.18	0.7	0.23	0.32	0.35	-0.3	0.48	0.66	-0.05		0.17	0.62	0.39	0.02	0.91
Current Deferred Revenue	0.4	0.33	0.17	0.48	0.37	0.54	-0.61	0.36	0.37	0.65	0.32	-0.12	0.45	0.27	0.14	0.29	-0.17	0.51	0.41	-0.23	0.17		0.23	0.08	-0.22	-0.01
Net Receivables	0.96	-0.07	-0.32	0.91	0.96	0.68	-0.35	0.96	0.95	0.42	0.88	0.04	0.93	0.15	0.87	0.45	-0.1	0.89	0.96	0.3	0.62	0.23		0.91	-0.7	0.61
Short Term Investments	0.86	-0.27	-0.22	0.87	0.85	0.62	0.0	0.87	0.92	0.08	0.87	0.01	0.79	-0.04	0.95	0.35	0.1	0.85	0.85	0.49	0.39	0.08	0.91		-0.83	0.47
Common Stock	-0.64	0.45	0.2	-0.75	-0.62	-0.6	-0.16	-0.65	-0.76	0.07	-0.67	0.25	-0.57	0.29	-0.84	-0.2	-0.26	-0.74	-0.63	-0.66	0.02	-0.22	-0.7	-0.83		-0.01
Other Liab	0.61	0.12	-0.21	0.47	0.65	0.1	-0.48	0.63	0.52	0.46	0.52	0.06	0.64	0.27	0.38	0.22	-0.22	0.41	0.62	-0.02	0.91	-0.01	0.61	0.47	-0.01

Click cells to compare fundamentals

Biosyent Account Relationship Matchups

Biosyent fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	31.0M	33.6M	37.2M	40.5M	41.5M	43.6M
Other Current Liab	198.8K	328.8K	98.7K	318.0K	138.4K	228.7K
Total Current Liabilities	3.4M	5.1M	4.1M	5.7M	5.5M	5.8M
Total Stockholder Equity	25.8M	26.8M	31.6M	33.4M	34.8M	36.5M
Property Plant And Equipment Net	2.5M	2.2M	1.9M	1.7M	1.4M	1.5M
Net Debt	(11.6M)	(18.6M)	(16.5M)	(6.5M)	(3.7M)	(3.9M)
Retained Earnings	17.5M	19.1M	24.1M	25.9M	27.5M	28.9M
Accounts Payable	2.9M	3.7M	3.6M	5.1M	5.1M	5.3M
Cash	13.4M	20.3M	18.0M	7.9M	4.9M	5.4M
Non Current Assets Total	4.1M	3.8M	3.1M	3.3M	5.7M	5.9M
Cash And Short Term Investments	22.0M	25.6M	28.2M	28.7M	26.2M	27.5M
Common Stock Shares Outstanding	13.9M	13.1M	12.9M	12.5M	12.2M	13.5M
Liabilities And Stockholders Equity	31.0M	33.6M	37.2M	40.5M	41.5M	43.6M
Inventory	2.1M	2.1M	2.2M	4.5M	5.9M	6.2M
Other Current Assets	648.8K	307.6K	456.0K	255.0K	243.5K	163.3K
Other Stockholder Equity	1.2M	1.5M	1.8M	2.2M	2.3M	3.1M
Total Liab	5.2M	6.8M	5.6M	7.1M	6.8M	7.1M
Total Current Assets	26.8M	29.8M	34.1M	37.1M	35.9M	37.7M
Intangible Assets	1.0M	1.0M	874.0K	1.2M	1.2M	660.8K
Current Deferred Revenue	99.1K	934.4K	313.6K	164.4K	134.5K	138.0K
Net Receivables	2.1M	1.8M	3.2M	3.7M	3.5M	3.7M
Accumulated Other Comprehensive Income	(105.3K)	(166.7K)	(185.3K)	(143.1K)	(177.5K)	(168.6K)
Short Term Investments	8.5M	5.3M	10.2M	20.8M	21.3M	22.3M
Common Stock	7.2M	6.4M	5.8M	5.4M	5.1M	5.4M
Other Liab	102.9K	79.7K	80.2K	182.4K	209.7K	153.4K
Net Tangible Assets	24.7M	25.8M	30.7M	32.3M	37.1M	21.9M
Other Assets	686.5K	758.8K	406.5K	639.1K	1.0	0.95
Non Current Liabilities Total	1.8M	1.6M	1.5M	1.4M	1.2M	851.1K
Property Plant Equipment	2.4M	2.1M	1.8M	1.6M	1.9M	961.5K
Deferred Long Term Liab	72.0K	131.0K	124.1K	170.6K	196.2K	98.8K
Net Invested Capital	25.8M	26.8M	31.6M	33.4M	34.8M	31.8M
Net Working Capital	23.5M	24.6M	29.9M	31.4M	30.3M	29.1M
Capital Stock	7.2M	6.4M	5.8M	5.4M	5.1M	5.0M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Biosyent Stock Analysis

When running Biosyent's price analysis, check to measure Biosyent's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biosyent is operating at the current time. Most of Biosyent's value examination focuses on studying past and present price action to predict the probability of Biosyent's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biosyent's price. Additionally, you may evaluate how the addition of Biosyent to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC